Laboratory of Cellular Pathology, Institute of Biology, Fluminense Federal University, Niteroi, RJ, 24020-141, Brazil.
Anticancer Res. 2013 Dec;33(12):5625-31.
This retrospective study aimed to evaluate the long-term response and toxicity of recurrent malignant glioma patients to inhalation chemotherapy with perillyl alcohol (POH).
The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154), grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival following treatment were compared with tumor size, topography, extent of peritumoral edema and histological classification.
Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely nosebleed. Tumor size, peritumoral edema and the oligodendroglial component influenced response to treatment.
After 4 years under exclusive POH treatment, 19% of patients still remain in clinical remission. Long-term POH inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma.
本回顾性研究旨在评估复发恶性胶质瘤患者接受叶绿醇（POH）吸入化疗的长期疗效和毒性。
该队列包括 117 名男性和 81 名女性，其中原发性多形性胶质母细胞瘤（GBM；n=154）、III 级星形细胞瘤（AA；n=26）和间变性少突胶质细胞瘤（AO；n=5）。POH 吸入方案为每日 4 次，起始剂量为 66.7mg/次；266mg/天，逐步增加至 133.4mg/次；533.6mg/天。治疗后的临床毒性和总生存期与肿瘤大小、位置、瘤周水肿程度和组织学分类进行了比较。
对方案的依从性很高（>95%），POH（533.6mg/天）偶尔会引起鼻痛，但很少引起鼻出血。肿瘤大小、瘤周水肿和少突胶质细胞成分影响治疗反应。
在单独接受 POH 治疗 4 年后，仍有 19%的患者保持临床缓解。长期 POH 吸入化疗是一种安全、非侵入性的策略，对复发性恶性胶质瘤有效。
